Evaluation of pain in patients with COVID-19

Objectives: A new type of coronavirus outbreak has emerged in China and caused a pandemic. World Health Organization (WHO) announced the official name of this disease ‘COVID-19’. The main purpose of this study is to evaluate pain in COVID-19 patients. Methods: Patients who were followed in the ward of an infectious diseases department because of possible or confirmed COVID-19 between May and September of 2020 were included in the study. The Turkish version of the Brief Pain Inventory (BPI) was applied. Demographic features, frequency, location, the intensity of pain, and response to analgesics were analyzed. Results: A total of 178 participants were included in the study. Ninety-one (51.1%) of patients had pain complaints and the mean pain score (MPS) was 2.28±2.81 over 10. Fifty-nine (56.0%) of participants with pain required analgesic therapy and 41 (80.3%) of them showed ≥50% pain relief with simple analgesics. Twelve of the remaining 18 who did not get enough pain relief with simple analgesic were taking their analgesics pro re nata (PRN) rather than around the clock (ATC). Pain frequency and intensity and mean hospitalization duration (MHD) were similar between confirmed and possible cases. Conclusion: Regarding the results, we conclude that pain is not one of the challenging symptoms and easily manageable in patients with a mild-moderate intensity of COVID-19. Our results were not enough to make a correlation between pain and the clinical course of the disease. Further studies are required for the evaluation of pain including patients in intensive care units.

Özet

Amaç: Yeni bir tip koronavirüs salgını Çin’de ortaya çıktı ve pandemik oldu. Dünya Sağlık Örgütü (DSÖ) bu hastalığın resmî adını ‘COVID-19’ olarak ilan etti. Bu çalışmanın ana amacı COVID-19 hastalarında ağrıyı değerlendirmektir. Gereç ve Yöntem: 2020 yılının Mayıs ve Eylül ayları arasında muhtemel veya kesin COVID-19 tanısıyla enfeksiyon hastalıkları servisinde takip edilmiş olan toplam 178 hasta çalışmaya dahil edildi. Kısa Ağrı Envanteri’nin (BPI) Türkçe versiyonu uygulandı. Demografik özellikler, ağrının sıklığı, lokasyonu, şiddeti ve analjeziklere yanıtı analiz edildi. Bulgular: Hastaların doksan birinde (%51.1) ağrı şikayeti vardı ve ortalama ağrı skoru (OAS) 10 uzerinden 2,28±2,81’di. Ağrısı olan hastalardan elli dokuzu (%56.0) ağrı kesiciye ihtiyac duydu ve kırk birinde (%80.3) basit ağrı kesicilerle yuzde elliden daha fazla ağrı azalması saptandı. Yeterli ağrı palyasyonu sağlanamayan on sekiz hastanın on ikisinin ağrı kesicilerini duzenli olarak almak yerine ağrı oldukca almış oldukları gozlendi. Muhtemel ve kesin vakaların ağrı frekansı, şiddeti ve hastanede kalış suresi benzerdi. Sonuç: Sonuçlarımıza göre COVID-19 hastalarında ağrının baş edilmesi zor bir semptom olmadığı ve hafif-orta klinik şiddet- teki hastalarda kolaylıkla tedavi edilebildiği kanaatine vardık. Sonuçlarımız ağrı ve hastalığın klinik seyri arasında bir bağlantı kurmak için yeterli değildi. Ağrı değerlendirmesi için yoğun bakım hastalarını içeren başka çalışmalara ihtiyaç vardır.

🔖

Cite This Article

TANYEL, E., DEVECİ, A., KURÇALOĞLU, M., KETENCİ, S., GÜLDOĞUŞ, F., ÖZKAN, F., BİLEK, H. C., ERBAŞ, S. N. (2022). Evaluation of pain in patients with COVID-19. Ağrı, Cilt: 33 - Sayı: 4, 215–222. https://ajindex.com/articles/430568

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (14)

Baj J, Karakula-Juchnowicz H, Teresinski G, Buszewicz G, Ciesielka M, Sitarz E, et al. COVID-19: Specific and non- specific clinical manifestations and symptoms: the current state of knowledge. J Clin Med 2020;9(6):1753
Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92(6):577–583
Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med 2020;383(18):1757–66
Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clini- cal characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect 2020;80(6):656–65
Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091
Li JY, You Z, Wang Q, Zhou ZJ, Qiu Y, Luo R, et al. The epi- demic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect 2020;22(2):80–5
Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, She- hata AA. The COVID-19 Pandemic: A Comprehensive Re- view of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control. J Clin Med 2020;9(4):1225
Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis 2020;94:154–5
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506
Borges do Nascimento IJ, Cacic N, Abdulazeem HM, von Groote TC, Jayarajah U, Weerasekara I, et al. Novel coro- navirus infection (COVID-19) in humans: a scoping review and meta-analysis. J Clin Med 2020;9(4):941
Zhang X, Cai H, Hu J, Lian J, Gu J, Zhang S, et al. Epide - miological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. Int J Infect Dis 2020;94:81–7
Bolay H, Gül A, Baykan B. COVID-19 is a real headache! Headache 2020;60(7):1415–21 13. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain 2004;5(2):133–7
Cleeland CS. Measurement of pain by subjective report. In: Chapman CR, Loeser JD, editors. Advances in Pain Re- search and Therapy. Vol
Issues in Pain Measurement. New Yor